Rakesh Pahwa1 
,
Vijay Soni1,
Prabodh Chander Sharma1,
Vipin Kumar1,
Kanchan Kohli2
For correspondence:- Rakesh Pahwa Email: rakeshpahwa2407@yahoo.co.in Tel:+919896250793
Received: 8 March 2010 Accepted: 15 October 2010 Published: 23 December 2010
Citation: Pahwa R, Soni V, Sharma PC, Kumar V, Kohli K. Arformoterol Tartrate: A Review of Pharmacology, Analysis and Clinical Studies. Trop J Pharm Res 2010; 9(6):595-603 doi: 10.4314/tjpr.v9i6.11
© 2010 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
This article is a review of the therapeutic significance of arformoterol tartrate, a new generation β2 adrenergic agonist bronchodilator available in a nebulized form. Arformoterol is well absorbed through the lungs when administered via a standard jet nebulizer and is useful in long-term maintenance therapy of bronchoconstriction in chronic obstructive pulmonary disease (COPD). Much clinical evidence suggest the potentially enhanced efficacy of this drug in the treatment of COPD including chronic bronchitis and emphysema. Various hyphenated analytical methodologies have also been employed for the determination and quantification of arformoterol. This review provides an updated account on the pharmacology, pharmacokinetics, clinical studies, analytical techniques, drug-drug interactions, contraindications, and therapeutic applications of arformoterol tartrate.
Archives
News Updates
Fulltext in PDF